Does ibogaine work for depression?

The 2023 Stanford study published in Nature Medicine found an average 87% decrease in depression symptoms in 30 treatment-resistant veterans at one month post-ibogaine treatment — past the point when both ibogaine and noribogaine had substantially cleared the body. The study had real limitations: no placebo arm, small sample size, and a specific population of people who had already tried conventional approaches without adequate relief. The direction is consistent with both the proposed mechanisms and clinical observation across multiple settings.

How long do the effects of ibogaine on depression last?

The active ceremony lasts 12–24 hours. Noribogaine — ibogaine's primary active metabolite — has a half-life of 28–49 hours and remains pharmacologically active for weeks. The Stanford study measured outcomes at one month post-treatment and found 87% reductions in depression symptoms. Whether those improvements are sustained depends substantially on integration work during the neuroplasticity window — typically 8–12 weeks — that noribogaine sustains. People who return to the same conditions without deliberate integration work frequently do not hold the initial improvements.

Can ibogaine treat anxiety?

The Stanford study found an average 81% decrease in anxiety symptoms in 30 treatment-resistant veterans at one month post-ibogaine treatment. The mechanism — serotonin transporter modulation, GDNF upregulation, and default mode network disruption — is consistent with anxiolytic effect. Ibogaine is not appropriate for someone in acute anxiety crisis, and the experience itself is not comfortable. It shows people what they have been avoiding. That is not a calming experience — it is a direct one.

Who should not use ibogaine for depression or anxiety?

Absolute contraindications include: anyone on SSRIs or SNRIs (serotonin syndrome risk is real and potentially fatal — a supervised taper with the prescribing physician is required first, not just a few days off the medication); QT prolongation, cardiac arrhythmia, or recent myocardial infarction; active psychosis or schizophrenia spectrum disorder; lithium; severe liver or kidney disease; pregnancy. People in acute psychiatric crisis and people primarily seeking the experience rather than the subsequent integration work are also not appropriate candidates.

Is ibogaine treatment for depression legal in Canada?

Ibogaine is not listed under Canada's Controlled Drugs and Substances Act and is not approved for medical use. It is not explicitly prohibited — a different legal position from the United States (Schedule I) or the United Kingdom (Class A). A small number of ceremonially-rooted providers operate legally in British Columbia. Medical screening including EKG and blood panel is required before any ceremony regardless of legal status.

What happens after ibogaine treatment for depression?

After the 12–24 hour ceremony, there is a 2–3 day physical recovery period — disrupted sleep, emotional sensitivity, and reduced appetite are normal. Noribogaine remains pharmacologically active for weeks, sustaining a neuroplasticity window during which the brain forms new connections more readily. Integration coaching during this window — structured support for translating ceremony insights into sustained behavioural change — is not optional for people seeking lasting improvement in depression. Without it, the window closes and the patterns that sustained the depression typically reassert.

Ibogaine for Depression and Anxiety: What the Research Shows

Q: How does ibogaine treat depression differently than SSRIs?

SSRIs block serotonin reuptake daily — a management model requiring ongoing medication to maintain effect. Ibogaine binds to the serotonin transporter at a different site, upregulates GDNF and BDNF (neurotrophic factors supporting neural repair and plasticity), and disrupts the default mode network — the brain's self-referential processing loop central to depressive rumination. A single ceremony produces effects sustained for weeks through noribogaine. The pharmacological breadth is wider and the mechanism differs in kind, not just degree. Ibogaine addresses treatment-resistant cases where antidepressants have not been enough — it is not a replacement for them.

Q: What did the Stanford study show about ibogaine for depression?

The 2023 Stanford study in Nature Medicine treated 30 special operations veterans with a single ibogaine session. One month later, researchers found an average 87% decrease in depression symptoms, 81% decrease in anxiety, and 88% decrease in PTSD. Both ibogaine and noribogaine had substantially cleared from the body by that measurement point, suggesting the outcomes are more durable than an acute pharmacological effect. Texas subsequently committed $50 million to clinical ibogaine trials at UTMB, UTHealth Houston, Texas A&M, and Baylor.

Ibogaine treatment for depression and anxiety works through mechanisms that SSRIs do not address. In the 2023 Stanford study, published in Nature Medicine, participants showed an average 87% decrease in depression symptoms and 81% decrease in anxiety at one month post-treatment. Those measurements were taken after both ibogaine and its metabolite had substantially cleared from the body — making them more difficult to attribute to an acute pharmacological effect. The medicine is not appropriate for everyone, and the people for whom it is not appropriate are not a small category.

Ibogaine treatment for depression and anxiety works by binding to the serotonin transporter at a different site than SSRIs, upregulating GDNF and BDNF (neurotrophic factors that support neural repair), and disrupting the default mode network — the brain's self-referential processing loop central to depressive rumination. Its active metabolite, noribogaine, sustains these effects for weeks following a single ceremony.

Dense foggy forest with tall trees disappearing into mist — ibogaine for depression and anxiety operates through neurological mechanisms distinct from antidepressants — Photo by eberhard grossgasteiger via Pexels

Golden sunlight streaming through a misty forest at dawn — ibogaine upregulates neurotrophic factors GDNF and BDNF that support neural repair and plasticity — Photo by John Finster via Pexels

How Ibogaine Affects the Brain

SSRIs increase serotonin availability by blocking its reuptake — they bind to the serotonin transporter (SERT) and prevent it from removing serotonin from synaptic gaps. Ibogaine binds to SERT as well, but at a different site. The effect is not identical, and ibogaine's action on serotonin is only one part of a wider pharmacological profile.

The more significant pathway for depression may be neuroplasticity. Ibogaine upregulates GDNF — Glial Cell Line-Derived Neurotrophic Factor — a protein that promotes neuron survival, growth, and repair. Noribogaine, the active metabolite ibogaine converts to in the body, also upregulates BDNF (Brain-Derived Neurotrophic Factor). Both are associated with antidepressant effect in preclinical research. Both support the formation of new neural connections.

The third mechanism is default mode network disruption. The DMN is the brain's self-referential processing system — the loop of rumination, negative self-appraisal, and rigid thought patterns that characterises depression. Ibogaine disrupts DMN activity. The result is a period during which those patterns are less entrenched and new patterns are more accessible.

Ibogaine acts simultaneously on serotonin, dopamine, NMDA, and sigma-2 receptors, alongside the neurotrophic upregulation. This pharmacological breadth is why its effects differ in kind from an SSRI — not just degree.

Doctor reviewing a medical form with a patient — ibogaine treatment for depression requires full medical screening including EKG and blood panel before any ceremony — Photo by MART PRODUCTION via Pexels

What the Research Shows

The primary data is from the 2023 Stanford study published in Nature Medicine. The study treated 30 special operations veterans with a single ibogaine session. The population: treatment-resistant PTSD, traumatic brain injury, depression, and substance use disorders — people who had tried other approaches and not found adequate relief.

At one month post-treatment, researchers measured: an average 87% decrease in depression symptoms, 81% decrease in anxiety symptoms, and 88% decrease in PTSD symptoms. Conventional antidepressant research considers a 50% reduction in depression scores a strong response. The one-month measurement point matters: both ibogaine and noribogaine had substantially cleared from the system by then. The improvements being measured are not an acute pharmacological effect.

Special operations veterans are not, as a population, people who arrive at anything naively. They had been through programmes. They had been given diagnoses and medications. Many were sceptical that anything was going to work. The Stanford numbers documented what practitioners had been observing for years — that ibogaine produces changes in treatment-resistant cases that conventional approaches do not.

The study has real limitations. 30 participants is a small sample. There was no placebo arm. These are genuine methodological constraints the researchers acknowledge. Citing these results without those caveats is not honest. The numbers are compelling enough to stand with the caveats included.

Following the study, Texas committed $50 million to clinical ibogaine trials at UTMB, UTHealth Houston, Texas A&M, and Baylor. A 2020 study in ACS Chemical Neuroscience found antidepressant-like effects in rats from a single administration of ibogaine or noribogaine — preclinical evidence supporting the mechanism.

Person holding an assortment of medication pills — SSRIs require daily administration to maintain effect; ibogaine produces changes sustained by noribogaine for weeks after a single ceremony — Photo by Anna Shvets via Pexels

How Ibogaine Differs from Antidepressants

SSRIs increase serotonin availability through daily inhibition of reuptake. The model is management — consistent medication to maintain effect, with the effect typically reversing when the medication is stopped.

Ibogaine does not require daily administration. A single ceremony produces neuroplasticity upregulation, DMN disruption, and neurotrophic factor elevation sustained for weeks through noribogaine. Whether those changes produce lasting improvement in depression depends on what the person does with the neuroplasticity window while it is open.

Ibogaine is not a cure for depression. It is a neurological reset — a window during which the patterns that sustain depression are less entrenched and new patterns are more possible. What happens in that window determines whether the ceremony produces lasting change. That is the distinction that matters more than the pharmacological mechanism.

The conditions most consistent with a positive outcome: treatment resistance — people who have tried SSRIs, SNRIs, or other pharmacological approaches without adequate relief. Ibogaine is not a first-line treatment for mild-to-moderate depression with no prior treatment history. It is most relevant where conventional approaches have been tried and have not been enough.

This means ibogaine is not in direct competition with antidepressants. The medicine is not for people who prefer not to take medication. It is for people for whom medication has not resolved the condition. Those are different populations.

Back view of a man meditating in stillness — the neuroplasticity window after ibogaine ceremony requires deliberate integration work to produce lasting change in depression and anxiety — Photo by Ajan Yogi via Pexels

The Noribogaine Window

After the 12–24 hour ceremony, ibogaine converts to noribogaine. Noribogaine's half-life is 28–49 hours — longer than ibogaine's — and it remains pharmacologically active for weeks. This sustained activity is the most plausible explanation for why the Stanford study's one-month measurements showed outcomes that resist attribution to the acute experience alone.

The neuroplasticity window noribogaine sustains — typically described as 8–12 weeks after ceremony — is not passive. It is a period during which the brain forms new neural connections more readily than it otherwise would. That window can close without any lasting change having occurred.

The ceremony was profound. The person left with clarity, reduced pull toward the familiar patterns that had sustained their depression, and what felt like the beginning of something different. Six weeks later, they were back where they started — or worse, because the contrast between what had been possible and what they had returned to was now sharper. This happens when people return to the environments, relationships, and unaddressed conditions that produced the problem in the first place. It happens when there is no integration support in place.

Integration coaching — structured support for translating the insights and pattern recognition from ceremony into sustained change — is not an afterthought. It is what determines whether the ceremony produces lasting change or a temporary altered state. The ceremony opens a window. Integration is the work done while the window is open.

For depression specifically, integration involves identifying what the ceremony revealed about the conditions sustaining it — and doing something specific about those conditions. Without that, the neuroplasticity window closes, and the patterns reassert.

Doctor in consultation with a patient — ibogaine for depression requires EKG screening, medication review, and psychiatric history assessment before any ceremony — Photo by cottonbro studio via Pexels

Who This Is Not For

The contraindications for ibogaine are not preferences. They are the conditions under which the medicine carries real risk of serious harm.

SSRIs and SNRIs are absolute contraindications.The risk of serotonin syndrome — from the interaction between ibogaine's serotonergic activity and the continued presence of an SSRI — is real and potentially fatal. A supervised taper, conducted with your prescribing physician, is required before ceremony is possible. Not a few days off the medication. A supervised taper. There are no exceptions.

Other absolute contraindications:

QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction. Ibogaine prolongs the QT interval. EKG screening before ceremony identifies cardiac risk that is often invisible in a standard medical history.
Active psychosis or schizophrenia spectrum disorder. Ibogaine amplifies what is present. Entering ceremony in a state of acute psychiatric instability does not produce insight — it produces destabilisation.
Lithium and certain other psychiatric medications. The interaction risks are documented.
Severe liver or kidney disease.
Pregnancy.

For depression specifically: someone in acute psychiatric crisis is not an appropriate candidate. The experience amplifies what is present. Ibogaine requires a baseline of psychological stability — not comfort, but the capacity to hold and engage with difficult autobiographical material.

People who are primarily seeking the experience rather than the work that follows are not appropriate candidates. Ibogaine shows people what they have been avoiding. The person who arrives expecting clarity without difficulty typically encounters exactly what they were hoping to avoid.

If you are not an appropriate candidate, we will say so directly — without softening it. The FAQ covers the full list of contraindications and what the screening process involves.

Is This Right for You?

Ibogaine treatment for depression and anxiety at ExploreBwiti in Vancouver is most appropriate for people with treatment-resistant conditions — those who have tried other approaches, have done meaningful medical and psychological preparation, and are committed to the integration work in the weeks that follow.

If you are currently on SSRIs or SNRIs, the conversation starts with your prescribing physician and a supervised taper. That taper is a prerequisite to ceremony. The timeline varies by medication — some require weeks, others months. This is not a step that can be skipped.

Ceremony at ExploreBwiti costs $2,000–$5,000 CAD, including the on-site medical professional, medicine, and facilitation. Integration coaching is $150–$300 per session. Both are components of the same process.

The FAQ covers what screening involves and what disqualifies someone from ceremony. The ibogaine duration guide explains the three phases and the recovery timeline. When you are ready to begin the conversation, the application is where it starts — we respond personally to every application within 2–3 business days.